Overview

CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant

Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
CD34+ stem cell selection in children, adolescents and young adults receiving partially matched family donor or matched unrelated adult donor allogeneic bone marrow or peripheral blood stem cell transplant will be safe and well tolerated and be associated with a low incidence of serious (Grade III/IV) acute and chronic graft versus host disease (GVHD).
Phase:
Phase 2
Details
Lead Sponsor:
New York Medical College
Treatments:
Alemtuzumab
Antilymphocyte Serum
Busulfan
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Thiotepa
Vidarabine